1. 1 Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
2. 2 Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
3. 3 Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, et al.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients : a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040-2045, 2010
4. 4 Siddhartha G, Vijay P: R-CHOP versus R-CVP in the treatment of follicular lymphoma : a meta-analysis and critical appraisal of current literature. J Hematol Oncol 2:14, 2009
5. 5 No authors listed : A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993